59938-33-9

Usage

Uses

Used in Pharmaceutical Industry:
3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE is used as a starting material for the synthesis of various biologically active molecules, contributing to the development of new drugs and pharmaceutical products. Its unique structure allows for the creation of compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE is utilized for its potential in the development of innovative drugs. Its properties are harnessed to design molecules that can interact with biological targets, offering new avenues for treatment and therapy.
Used in Agrochemicals:
3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE has been investigated for its potential use in agrochemicals, where it may serve as a key component in the synthesis of compounds that address various agricultural needs, such as pest control and crop protection.
Used in Other Industrial Applications:
Beyond its applications in the pharmaceutical and agrochemical sectors, 3-IODO-7-METHYL-IMIDAZO[1,2-A]PYRIDINE is also explored for use in other industrial applications, capitalizing on its chemical properties to create novel products and materials.

Upstream product

• 874-39-5 7-Methyl-imidazo[1,2-a]pyridine 
• 695-34-1 2-Amino-4-methylpyridine 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES

Novel imidazo[1,2-α]pyridinyl bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

NEW COMPOUNDS

The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.